Israeli biotech Redhill has announced that the Phase 3 trial of its BEKINDA treatment for acute gastroenteritis and gastritis, on 321 patients in 21 US clinical sites, met its targets for efficacy and safety. There are some 179 million cases of gastroenteritis annually in the US.

http://www.timesofisrael.com/israels-redhill-says-gastroenteritis-drug-found-safe-in-study/